EQUITY (Tables)

12 Months Ended

Dec. 31, 2022

EQUITY

Schedule of outstanding and exercisable options

Outstanding and exercisable options for Intel’s common stock under Intel’s 2006 Plan as of December 31, 2022 were as follows:

	Outstanding				Exercisable
		Weighted average	Weighted			Weighted
	Number of	remaining	average		Number of	average
Exercise price	options	contractual life	exercise price		options	exercise price
U.S. dollars	In thousands	In years	U.S. dollars		In thousands	U.S. dollars
$ 4.0 - 21.6	66	2.9	$	7.6	30	$	5.8
$ 22.4 - 26.9	2,136	0.6		26.8	2,136		26.8
$55.2	68	6.3		55.2	45		55.2
Total	2,270	0.8	$	27.1	2,211	$	27.1

Schedule of option activity

		Weighted
		average	Weighted		Aggregated
	Number of	remaining	average		intrinsic
	options	contractual Life	exercise price		value(1)
	In thousands	In years	U.S. dollars		U.S. dollars in millions
Options outstanding as of December 28, 2019	6,594	3.4	$	29.1	$	204
Exercised	(173)	—		23.4		—
Forfeited	(30)	—		19.5		—
Options outstanding as of December 26, 2020	6,391	2.4		29.2		114
Exercised	(2,807)	—		29.3		—
Forfeited	(6)	—		24.5		—
Options outstanding as of December 25, 2021	3,578	1.5		29.2		79
Exercised	(1,308)	—		32.8		—
Options outstanding as of December 31, 2022	2,270	0.8	$	27.1	$	1
Options exercisable as of December 31, 2022	2,211	0.8	$	27.1	$	1

Schedule of RSU activity

The RSU activity for the year ended December 31, 2022 for RSUs granted to Company’s employees under the 2022 Plan was as follows:

		Weighted average grant
	Number of RSUs	date fair value
	In thousands	U.S. dollars
Outstanding as of December 25, 2021	—	$	—
Granted	12,570		21
Forfeited	(6)		21
Outstanding as of December 31, 2022	12,564	$	21

The RSU activity for the years ended December 31, 2022, December 25, 2021, and December 26, 2020 for RSUs granted to Company’s employees for Intel’s common stock was as follows:

		Weighted average grant
	Number of RSUs	date fair value
	In thousands	U.S. dollars
Outstanding as of December 28, 2019	2,371	$	43.2
Granted	3,628		44.4
Vested	(1,588)		42.0
Forfeited	(72)		47.4
Outstanding as of December 26, 2020	4,339		44.6
Granted	2,935		47.8
Vested	(1,761)		44.0
Forfeited	(235)		46.4
Outstanding as of December 25, 2021	5,278		46.5
Granted	3,758		43.7
Vested	(2,935)		45.9
Forfeited	(409)		48.1
Outstanding as of December 31, 2022	5,692	$	44.8

Schedule of share-based compensation expenses

	Year ended
U.S. dollars in millions	December 31,		December 25,		December 26,
	2022		2021		2020
Cost of revenue	$	2	$	1	$	—
Research and development, net		153		77		67
Sales and marketing		5		4		3
General and administrative		14		15		15
Total share-based compensation	$	174	$	97	$	85